Incidence on relapse and nonrelapse mortality (NRM) of chronic graft-versus-host disease (GVHD), per National Institutes of Health (NIH) criteria, is not well defined after reduced-intensity conditioning (RIC) regimens. We analyzed the association of chronic GVHD with the risk of relapse and NRM using Cox models in 177 consecutive patients who underwent transplantation for hematological malignancies after RIC. The cumulative incidence of chronic GVHD at 36 months was 74% when using Seattle's criteria compared with 54% with NIH consensus. In Cox model, NRM was significantly higher in patients with late-onset, persistent and recurrent acute GVHD (hazard ratio (HR): 6, 25 and 11; P ¼ 0.014, Po0.0001, Po0.0001, respectively). The cumulative incidence of relapse was significantly decreased in patients with chronic GVHD compared with no GVHD group using either Seattle's or NIH criteria (HR 0.43 and 0.38; P ¼ 0.022 and 0.016, respectively), whereas the presence of late-onset, persistent and recurrent acute GVHD was not associated with a decreased rate of relapse (HR: not significant, 0.70 and 0.71; P ¼ not significant, P ¼ 0.73 and P ¼ 0.54, respectively). Chronic GVHD per NIH consensus definition is associated with the graft-versus-tumor effect, whereas all forms associated with acute features beyond day 100 are associated with NRM.
Introduction
Graft-versus-host disease (GVHD) is a common immunemediated disorder that occurs frequently after allogeneic hematopoietic stem cell transplantation (HSCT) and has an impact on morbidity and survival. 1 Historically, GVHD has been classified as acute and chronic according to the time of onset using the Seattle 100-day landmark, after which any GVHD is called chronic GVHD. However, with advances in HSCT practice in the past decade, especially with the development of the reduced-intensity conditioning (RIC) regimen, it is increasingly recognized that clinical syndromes resembling acute GVHD could occur for more than 100 days after HSCT or donor leukocyte infusion, whereas earlier onset of chronic GVHD might develop. 2 In addition, manifestations of both acute and chronic GVHDs can present simultaneously, and may be labeled as chronic GVHD. This syndrome thus includes extremely heterogeneous manifestations under the same name of chronic GVHD. Recognizing these limitations, the National Institutes of Health (NIH) sponsored in 2005 a consensus conference that proposed new criteria for the diagnosis, organ scoring and global assessment of chronic GVHD severity, which emphasized the manifestations of GVHD rather than the time of onset. 3 Chronic GVHD is also closely related to graft-versus-tumor effect. 4 Whether the late acute form of GVHD would have the same potential in reducing relapse rate as classical chronic GVHD is unknown. Although few studies have evaluated the incidence and outcome of chronic GVHD using NIH consensus criteria, [5] [6] [7] [8] [9] the incidence and impact of chronic GVHD manifestations defined per NIH consensus criteria after RIC have not been specifically evaluated.
In this study, we retrospectively reclassified a cohort of 177 patients with hematological malignancies who received allogeneic HSCT after RIC using both the NIH consensus criteria and the revised Seattle criteria. The aim of this study was to determine the incidence and outcomes of the various subtypes of GVHD after day 100 of the HSCT, and especially their impact on the rate of relapse and of nonrelapse mortality (NRM).
Materials and methods
This study included all 192 consecutive patients who underwent HSCT after an RIC regimen for hematological malignancies at Saint Louis Hospital between October 2001 and January 2009 for whom data were prospectively collected. All patients gave written consent allowing the use of medical records for research, in accordance with the Declaration of Helsinki. Patients with the following criteria were excluded in order to secure a homogeneous cohort: patients who died or who experienced relapse before day 100 after transplant (n ¼ 13) and those who had undergone previous allogeneic SCT (n ¼ 2). The final study cohort comprised of 177 patients. We retrospectively reviewed the medical history of all these patients detailed information regarding age, sex, diagnosis, disease status at transplant, human leukocyte antigen (HLA) matching, conditioning regimen, cytomegalovirus serology status, GVHD prophylaxis, diagnosis criteria for GVHD and type of onset and organ-specific involvement. Pertinent laboratory results (including liver function tests, white blood cell count with differential, hemoglobin, platelet count, and pulmonary functionary tests) were also collected. The pretreatment characteristics of these patients are summarized in Table 1 . Of note, all patients had chemosensitive malignancies. All patients with lymphoma and myeloma had relapsed after a previous autologous transplantation. Median age was 52 (6-68) years, initial disease was acute leukemia in 37 patients (21%), lymphoma in 43 (24%), plasma cell disorder in 40 (23%), myeloproliferative or myelodysplastic disorders in 42 (24%) and chronic lymphocytic leukemia in 15 (8%). 
Transplant procedures

GVHD prophylaxis and treatment
Standard GVHD prophylaxis regimen with cyclosporine (CsA) 2.5 mg/kg every 12 h from day À1, plus mycophenolate mofetil (MMF) 30 mg/kg per day, was used from day þ 1 in all but one patient. GVHD prophylaxis was as follows. MMF was administered until day þ 30, then stopped; CsA tapering was started on day þ 90 and stopped on day þ 180 if GVHD did not flare. All patients were graded weekly for acute GVHD using the Glucksberg's criteria until day 100, and the maximum grade was used. 10 The first-line treatment for grade II or higher acute GVHD consisted of methyl prednisone 2 mg/kg or an equivalent dose of prednisone for 7-14 days, followed by a decrease of 10% every 7 days. Treatment of steroid-refractory GVHD was variable in this period, included antithymocyte globulin, or an anti-interleukin 25 monoclonal antibody or an anti-tumor necrosis factor monoclonal antibody. Before day 100, 83 patients (47%) had no or grade I acute GVHD, 76 (43%) grade II GVHD and 18 patients (10%) had grade III or IV.
Patients with persistent or new occurrence of GVHD after day 100 after transplantation were classified as chronic GVHD and were stratified as limited or extensive based on the revised Seattle criteria.
11 Treatment was variable but followed some general principles. Patients with limited chronic GVHD were treated with topical steroids, whereas patients with extensive chronic GVHD were treated with systemic steroids and continued administration of calcineurin inhibitor.
Classification of chronic GVHD
Patients with only distinctive manifestations of acute GVHD after day 100 after transplantation or features of chronic GVHD regardless of the time after transplantation were classified using NIH consensus criteria. GVHD beyond day þ 100 patients with features of classic acute GVHD were classified as persistent, recurrent or delayed acute GVHD. 3 Chronic GVHD was diagnosed if the patient presented at least one diagnostic clinical sign of chronic GVHD or at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests and exclusion of other possible diagnosis. For persistent acute GVHD, the assessment was assigned at day 100, and for other subtypes of GVHD the assessment was assigned at the onset of manifestations that met the NIH consensus criteria. In case of transitions from late acute GVHD to NIH chronic GVHD, a date of the onset of NIH chronic GVHD was assigned, and the patient was considered as having NIH chronic GVHD thereafter.
Statistical analysis
To identify factors affecting clinical outcomes, the following clinical parameters were assessed: patient age, gender, diagnosis, disease status at transplantation, donor type, HLA match, stem cell source, donor-recipient sex match, cytomegalovirus status, conditioning regimen, white blood cell count, hemoglobin level, platelet count and bilirubin level at the time of Abbreviations: ATG, antithymocyte globulin; CMV, cytomegalovirus; GVHD, graft-versus-host disease; HLA, human leukocyte antigen. a All 2 Gy except one 4 Gy. Only 49 transplants (28%) were performed for early-stage disease (that is, first complete remission or chronic phase). Only four patients had o18 years.
GVHD-associated GvL after RIC S Thepot et al GVHD diagnosis, presence of acute GVHD before day 100, subtype proposed by Seattle day 100 criteria and NIH consensus criteria, as well as global scoring of chronic GVHD (only patients with chronic GVHD defined by NIH criteria, such as classic chronic GVHD and overlap syndrome, were evaluated).
Cumulative incidence function 12 of GVHD according to classification criteria was computed using death and relapse/ progression as a competing events. Failure times were counted from 100 days after transplant, whereas some NIH consensus chronic GVHD with onset time before 100 days were counted from the onset time. Follow-up was censored at the time when patients underwent donor lymphocyte infusion or a second transplant without relapse or progression.
Two major statistic end points of this study to assess the impact of different subtypes of GVHD on major outcomes were GVHD-specific relapse/progression risk (RR) and GVHD-specific NRM and recurrent malignancy.
The impact of different subtypes of GVHD on the risk of relapse/progression (RR) and NRM was assessed using timedependent covariates in cause-specific proportional hazards models. In these analyses, all models had time of origin at day 100 after transplant. Patients were allowed to transition from one subtype to another, except patients with classic chronic GVHD could not transition back to overlap syndrome. The ability of the two GVHD classifications to predict NRM was compared using the discrimination index (c-index) for timedependent variables 13 and the model likelihood by Akaike's information criterion (AIC).
14 Briefly, AIC is a model-selection criterion penalized by the number of parameters in the model. It thus allows comparison of different statistical models fitted on the same data, which may have different number of parameters and which are not necessarily nested. The model with lowest AIC is considered as providing the best trade-off between bias and variance. In the present case, it allowed accounting for different numbers of subtypes among classifications. Cox proportional cause-specific hazards models were used to assess the association of baseline covariates with both end points.
To illustrate graphically the results, cumulative incidence function of RR and NRM were drawn according to the occurrence of chronic GVHD, separately for each classification. Incidence of RR and NRM without chronic GVHD was counted from 100 days after transplant and occurrence of chronic GVHD according to the classification analyzed was considered as a competing risk. Patients who experienced chronic GVHD were thus considered at risk of RR and/or NRM until the occurrence of chronic GVHD. Cumulative incidence function of RR and NRM after chronic GVHD was counted from chronic GVHD onset. Patients with relapse/progression before chronic GVHD onset were considered as not having chronic GVHD in these analyses. Patients were censored at the time of relapse. Donor leukocyte infusion (n ¼ 1) or transplant in a patient without relapse (n ¼ 1) due to persistent low chimerism was also censored.
Statistical analyses were performed using R software (version 2.9.1; R foundation for Statisitcal Computing, Vienna, Austria).
Results
Chronic GVHD according to Seattle's criteria
After a median follow-up of 28 months after transplant (5-92 months), among the 177 patients who were enrolled in this study, a total of 121 patients developed chronic GVHD as defined by Seattle's criteria beyond day 100 (Table 2) . These 121 chronic GVHD were, according to Seattle's criteria considered as de novo in 34 patients (28%), progressive in 67 (55%) and quiescent in 20 (17%) patients; (Table 3) , resulting in a 3-year confidence interval (CI) of 74% (Table 4) . Table 2 Comparison of GVHD classification (n (%)) Two later transformed to classic chronic, two to overlap syndrome. c Two later transformed to classic chronic, two to overlap syndrome. Percentage sums up to 4100 because of transformation to NIH consensus chronic GVHD.
Table 3
Comparison of GVHD classifications (n (%)) NIH consensus criteria Old criteria for chronic GVHD Percentage sums up to 4100% because of transformation to NIH consensus chronic GVHD.
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Chronic GVHD according to NIH criteria These patients were then reclassified according to the presence of clinical distinctive GVHD manifestations, as proposed by the NIH criteria (Table 3) . A total of 84 patients were reclassified as NIH chronic GVHD, resulting in a 3-year CI of 53.7% (classical chronic GVHD: n ¼ 66; overlap syndrome: n ¼ 18). The remaining 46 patients were reclassified as having delayed onset, persistent and recurrent acute GVHD (n ¼ 5, 13 and 27, respectively), resulting in a 3-year CI of 2.8%. Among these forty-six patients, five later transformed to chronic classic GVHD, whereas four of them later transformed to overlap syndrome (Figure 1 ).
NRM and relapse rate according to NIH and Seattle's criteria
The cumulative incidence at 24 months of relapse or progression and NRM in chronic GVHD patients was 9.7 and 36.4%, respectively, compared with no chronic GVHD patients, 16.5 and 1.3% using Seattle criteria. According to the NIH criteria, CIs of relapse or progression and NRM were 9.8 and 22.7% in patients with chronic GVHD and 17.7 and 15.3% in patients without chronic GVHD, respectively ( Figure 2 and Table 5 ). In a Cox model with GVHD as a time-dependent covariate, the NRM was significantly higher in patients with late-onset, persistent and recurrent acute GVHD compared with patients without chronic GVHD (hazard ratio (HR): 6, 25 and 11; P ¼ 0.014, Po0.0001, Po0.0001, respectively), whereas the NRM was less increased in case of NIH chronic GVHD (HR: 2.5; P ¼ 0.015). When using the day 100 criteria, the NRM also statistically increased (HR: 22.1; Po0.0001). The CI of relapse was significantly decreased in patients with chronic GVHD Table 4 Cumulative incidence of GVHD according to various definitions
GVHD classification
Cumulative incidence (95% CI) at 36 months Cumulative incidence (probability)
Months from 100 days after transplant 
Seattle's criteria NIH consensus criteria
No cGVHD cGVHD
No GVHD Classic chronic/overlap GVHD Late acute GVHD Cumulative incidence of relapse (probability) Cumulative incidence of relapse (probability) Figure 2 Relapse and NRM for patients with or without chronic GVHD, according to the classification criteria. Incidence of relapse and NRM without chronic GVHD was counted from 100 days after transplant. Occurrence of chronic GVHD was considered a competing risk. Incidence of relapse and NRM after chronic GVHD was counted from chronic GVHD onset. Chronic GVHD occurring after relapse or progression were not considered, as in previous analyses. Separate analyses were thus conducted for the different classification criteria. The association of occurrence of chronic GVHD with the risk of relapse and nonrelapse death was analyzed using time-dependent covariates in cause-specific proportional hazards models. In these analyses, all models had time of origin at day 100 after transplant.
GVHD-associated GvL after RIC S Thepot et al compared with no GVHD group when using both Seattle's and NIH criteria (HR: 0.43 and 0.38; P ¼ 0.022 and 0.016, respectively), whereas the presence of late-onset, persistent and recurrent acute GVHD was not associated with a decreased rate of relapse (Table 6 ). Receiving graft from unrelated donor and previous grade II-IV acute GVHD were associated with higher NRM (P ¼ 0.024 and 0.003, respectively), whereas only patients with plasma cell disorders showed higher risk of disease relapse/progression (Po0.0001) ( Table 7) .
We finally compared the two classifications for their ability to predict NRM: the c-index for time-dependent variables was 0.778 for the Seattle's classification and 0.821 for NIH consensus, and AIC was 338.0 versus 326.8, respectively. Thus, the ability of the NIH consensus criteria to discriminate between patients who died from NRM to others was higher than previous chronic GVHD criteria, as shown by the respective values of c-indexes. Moreover, the lower AIC value for the new classification also showed that it better fitted the risk of NRM. Abbreviations: GVHD, graft-versus-host disease; NIH, National Institutes of Health; NRM, nonrelapse mortality. 
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Discussion
Our study involving 177 patients, who underwent allogeneic SCT after an RIC, showed that over half of the patients developed chronic GVHD, using the NIH criteria. Although NRM was mainly associated with GVHD with acute features, the GVHD-associated graft-versus-leukemia (GvL) effect was associated with chronic GVHD, which leads to significant decreased hazard of relapse (nearly 60%) compared with no GVHD, whereas the presence of any form of acute GVHD was not associated with a decreased relapse rate. It was recognized as early as 1956 that transplanted allogeneic immunocompetent cells could eliminate leukemic cells in mice independent of chemoradiotherapy. 15 This was termed GvL. Initial evidence for GvL effects in humans came from studies reporting reduced leukemic relapse rates in allografted patients, especially in those who developed chronic GVHD compared with patients who did not. 16 GvL effects were confirmed by other investigators who observed increased risks of relapse in patients receiving T-cell-depleted and syngeneic transplantations. 17, 18 Direct support for antitumor effects of allogeneic cells came from observations that donor lymphocyte infusions could induce complete remissions in some patients with hematologic malignancies who had relapsed after allogeneic hematopoietic cell transplantation. 19 The use of reduced-intensity [20] [21] [22] and truly nonmyeloablative conditioning regimens 23, 24 has shifted some of the burden of tumor cell kill from the conditioning regimens to the GvL effects. These regimens are less toxic than conventional regimens and allow for treatment of older patients and patients with comorbid conditions. 25, 26 Using a nonmyeloablative regimen combining fludarabine and low-dose total body irradiation, the Seattle group reported that extensive chronic GVHD was associated with decreased risk of relapse or progression and increased probability of progression-free survival, whereas grade II-IV acute GVHD had no significant impact on the risk of relapse or progression but was associated with increased risk of NRM. 27 However this study did not use the NIH criteria to classify chronic GVHD 3 and it remains unclear (using these criteria) whether the GvL effect after RIC is mainly associated with chronic GVHD after RIC.
To our knowledge, this study is the first series that evaluates the incidence of NIH chronic GVHD in a large cohort of patients who exclusively received an RIC. The 33-month cumulative incidence of GVHD was 53.7%, and for late-onset acute GVHD it was 2.8%. In this study, we clearly show the difference of cumulative incidence of chronic GVHD between two classification systems. The cumulative incidence of chronic GVHD decreases about 20% when using NIH consensus criteria compared with the Seattle's criteria in our cohort. This proportion of patients with late acute GVHD was lower than that in previously published retrospective studies (15-48%). [5] [6] [7] [8] [9] But these studies mixed patients who underwent SCT after myeloablative conditioning and RIC, and for the Seattle's group study patients after myeloablative conditioning who received systemic treatment for chronic GVHD. 5 Our main interest was to search in which disease category, according to the NIH criteria, the GvL effect segregates. We were able to show that the main effect was within chronic GVHD (either classical or overlap syndrome). Other factors associated with relapse were decreased risk if transplant was performed from an unrelated donor, whereas patients with multiple myeloma showed higher risk of disease relapse/progression. It has to be stressed that all patients who underwent allogeneic SCT for myeloma in this series had chemotherapy-sensitive relapse after a previous autologous transplant and thus had high risk of disease relapse.
We finally compared the two classifications for their ability to predict NRM. The ability of the NIH consensus criteria to discriminate between patients who died from NRM to others was higher than previous chronic GVHD criteria, as shown by the respective values of c-indexes. Moreover, the lower AIC value for the new classification also showed that it better fitted the risk of NRM. We found an increased risk of NRM in patients with late acute GVHD in our cohort of patients. This result was found for myeloablative conditioning in three out of the five previous studies aiming to reclassify chronic GVHD according to the NIH consensus. [5] [6] [7] [8] [9] Although our study highlights the strong GvL effect of chronic GVHD in the setting of RIC, it has the pitfall of being a retrospective analysis. As all patients on study were followed up in our institution, medical records during follow-up allowed a quite well estimate of disease category but did not allow retrospective assignment into NIH-proposed severity scale. Prospective validations of the NIH classification are underway worldwide. These studies will be able to confirm our results on GvL effect after RIC.
As GvL effect was mainly restricted in patients with chronic GVHD and late acute manifestation of GVHD mostly accounted for NRM, much attention should be paid on prophylaxis and treatment of this latter manifestation.
